PFE - Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence | Benzinga
Monday, Bayer AG (OTC: BAYRY) (OTC: BAYZF) stopped the OCEANIC-AF Phase 3 study early after asundexian showed inferiority to Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc's (NYSE: PFE) apixaban (Eliquis).
William Blair writes that the trial's unexpected outcome after an 11-month initiation period contrasts with recent positive study results that indicated similar rates of stroke or systemic embolism but with a significant decrease in bleeding risk.
Data from milvexian, an oral Factor XIa inhibitor by Bristol Myers, and privately held Anthos Therapeutics Inc's abelacimab in total knee replacement ...